PF 477736
Code | Size | Price |
---|
TAR-T6028-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6028-2mg | 2mg | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6028-5mg | 5mg | £128.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6028-1mL | 1 mL * 10 mM (in DMSO) | £134.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6028-10mg | 10mg | £173.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6028-25mg | 25mg | £253.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
CAS:
952021-60-2
Formula:
C22H25N7O2
Molecular Weight:
419.489
Pathway:
Chromatin/Epigenetic; Angiogenesis; Apoptosis; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors
Purity:
0.9834
SMILES:
Cn1cc(cn1)-c1[nH]c2cc(NC(=O)[C@H](N)C3CCCCC3)cc3c2c1cn[nH]c3=O
Target:
c-Fms; VEGFR; FGFR; FLT; c-RET; Chk; CDK; Src; Aurora Kinase
References
Zhang C, et al. Clin Cancer Res, 2009, 15(14), 4630-4640.
Carrassa L, et al. Cell Cycle, 2012, 11(13), 2507-2517.
Chakraborty J, et al. J Biol Chem, 2010, 285(43), 33104-33112.
Blasina A, et al. Mol Cancer Ther, 2008, 7(8), 2394-2404.